Why is ovarian cancer so hard to detect?
Advanced stage ovarian cancer has a survival rate of 17% and yet, today, there is still no screening test for the nearly 4 billion women on the planet. The reason for this is existing technologies lack the combined sensitivity and specificity to detect cancer biomarkers at very early stages when the disease is still treatable and advancement to later stages can be prevented.
MedInvest Oncology Investor Conference, in Palo Alto, CA, on December 5-6, 2023
We are thrilled to announce @GenEndeavor’s participation in the upcoming MedInvest Oncology Investor Conference, in Palo Alto, CA, on December 5-6, 2023.
At the event, GenEndeavor will showcase our molecular diagnostics technology platform, which lowers the limit of detection of rare mutations and rapidly identifies pathogens for sensitive and real-time genetic and infectious disease detection. GenEndeavor’s current focus is to translate this new platform into an early-detection ovarian cancer screening test.
Jill Biden Announces Women's Health Research Initiative
Today First Lady Jill Biden announced an important initiative focused on womens’ health research. The announcement brings awareness to and underscores the need to bridge the gaps that exist today to finding solutions to the most significant women’s health care conditions and diseases that currently have eluded detection and treatment.
At GENENDEAVOR LLC, we are focused on developing an early-detection ovarian cancer test in an effort to, one day, make very early ovarian cancer screening possible, which today does not exist anywhere in the world. Today’s announcement is a very positive first step in the direction of enabling a potentially new generation of research initiatives that could help make ovarian cancer screening a reality.